Department of Diagnostic Pathology, Shizuoka Cancer Center Hospital, Sunto, Japan.
Department of Pathology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan.
J Cutan Pathol. 2022 Apr;49(4):393-398. doi: 10.1111/cup.14171. Epub 2021 Nov 28.
Langerhans cell histiocytosis (LCH) is a neoplastic condition of Langerhans cells, and can be associated with other neoplasms, especially BRAF-mutant hematological tumors and papillary thyroid carcinoma. Here we present the first case of co-existing LCH and low cumulative sun damage (low-CSD) melanoma, both of which had a BRAF V600E mutation. A 49-year-old man had a 45 × 43 × 15 mm semi-pedunculated, pigmented tumor in his back but had no other systemic symptoms. Histopathology revealed a 2-mm-sized incidental focus of LCH within a large lesion of low-CSD melanoma. Diffuse immunoexpression of CD1a, langerin/CD207, S100 protein, and BRAF (VE1) was observed in the focus of LCH. Sanger sequencing with microdissection confirmed BRAF V600E mutation in the component of LCH. Interestingly, the advanced melanoma also harbored the same BRAF V600E mutation, although the significance of this tumor combination is still unknown.
朗格汉斯细胞组织细胞增生症(LCH)是朗格汉斯细胞的肿瘤性疾病,可与其他肿瘤相关,尤其是 BRAF 突变的血液系统肿瘤和甲状腺乳头状癌。在此,我们报告首例共存的朗格汉斯细胞组织细胞增生症和低累积日光损伤(low-CSD)黑色素瘤,两者均存在 BRAF V600E 突变。一位 49 岁男性背部有一个 45×43×15mm 的半有蒂、色素性肿瘤,但无其他全身症状。组织病理学显示,在一个大的低-CSD 黑色素瘤病变中存在一个 2mm 大小的偶然朗格汉斯细胞组织细胞增生症病灶。该朗格汉斯细胞组织细胞增生症病灶弥漫表达 CD1a、 langerin/CD207、S100 蛋白和 BRAF(VE1)。微切割 Sanger 测序证实了 LCH 成分中的 BRAF V600E 突变。有趣的是,晚期黑色素瘤也携带相同的 BRAF V600E 突变,尽管这种肿瘤组合的意义尚不清楚。